Pomdoctor Limited Announces Receipt of Nasdaq Notice

Press Release: POMDOCTOR LIMITED Drive Internet Hospital Growth Through Strengthened Strategic Partnerships With Pharmaceutical Companies

Pomdoctor H1 EPS $(1.60), Sales $24.400M

Pomdoctor Ltd. HY net loss attributable to shareholders at USD 66.7 million, down over six times

Press Release: POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

US Stock Movement | PomDoctor (POM.US) Falls Nearly 4% in After-Hours Trading Following 0.75% Gain on Nasdaq Debut

Stock Track | PomDoctor Plunges 7.90% After Hours Following Volatile IPO Debut

Stock Track | PomDoctor Surges 7.20% After-Hours Following Successful Nasdaq Debut

Stock Track | PomDoctor Soars 7.20% in After-Hours Trading Following Successful Nasdaq IPO

Stock Track | PomDoctor Plummets 6.25% on IPO Day Despite Initial Gains

Stock Track | PomDoctor Plummets 6.25% After Initial IPO Surge, Investors Reassess

Stock Track | PomDoctor Soars 12.50% in Intraday Trading Following Nasdaq IPO

Pomdoctor Prices Roughly $20 Million IPO

BRIEF-Pomdoctor Limited Announces Pricing Of Initial Public Offering

Pomdoctor Ltd: Approved for Listing on Nasdaq Under Ticker Symbol "Pom"

Pomdoctor Limited Announces Pricing of Initial Public Offering

Pomdoctor Ltd - Pricing of IPO of 5,000,004 Adss at a Public Offering Price of US$4.00 per Ads

Polyplastics' DURAST (R) Fine Powder Technology Unleashes New Manufacturing Possibilities for Engineering Plastics